Literature DB >> 22806348

HIV peripheral neuropathy progression: protection with glucose-lowering drugs?

Scott R Evans1, Anthony J Lee, Ronald J Ellis, Huichao Chen, Kunling Wu, Ronald J Bosch, David B Clifford.   

Abstract

The purpose of this study is to evaluate risk factors for progression from asymptomatic peripheral neuropathy (APN) to symptomatic peripheral neuropathy (SPN). Antiretroviral therapy (ART)-naïve patients initiating combination ART were followed longitudinally and screened for signs/symptoms of PN. Having APN was associated with higher odds of future SPN (odds ratio (OR) = 1.58, 95 % confidence interval (CI) = (1.08, 2.29), p = 0.027). Neurotoxic ART use was associated with increased odds of progression to SPN (OR = 2.16, 95 % CI = (1.21, 3.85), p = 0.009) while use of glucose-lowering drugs (non-insulin) was protective (OR = 0.12, 95 % CI = (0.02, 0.83), p = 0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806348      PMCID: PMC3485691          DOI: 10.1007/s13365-012-0119-9

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  17 in total

1.  Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.

Authors:  Alan L Landay; John Spritzler; Harold Kessler; Donna Mildvan; Minya Pu; Larry Fox; Dorothy O'Neil; Barbara Schock; Daniel Kuritzkes; Michael M Lederman
Journal:  J Infect Dis       Date:  2003-11-13       Impact factor: 5.226

2.  A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

Authors:  Margaret A Fischl; Heather J Ribaudo; Ann C Collier; Alejo Erice; Marina Giuliano; Marjorie Dehlinger; Joseph J Eron; Michael S Saag; Scott M Hammer; Stefano Vella; Gene D Morse; Judith E Feinberg; Lisa M Demeter; Susan H Eshleman
Journal:  J Infect Dis       Date:  2003-08-15       Impact factor: 5.226

3.  A comparison of goodness of fit tests for the logistic GEE model.

Authors:  Scott Evans; Lingling Li
Journal:  Stat Med       Date:  2005-04-30       Impact factor: 2.373

4.  The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).

Authors:  J J Eron; L M Smeaton; S A Fiscus; R M Gulick; J S Currier; J L Lennox; R T D'Aquila; M D Rogers; R Tung; R L Murphy
Journal:  J Infect Dis       Date:  2000-04-26       Impact factor: 5.226

5.  Peripheral neuropathy in HIV: prevalence and risk factors.

Authors:  Scott R Evans; Ronald J Ellis; Huichao Chen; Tzu-min Yeh; Anthony J Lee; Giovanni Schifitto; Kunling Wu; Ronald J Bosch; Justin C McArthur; David M Simpson; David B Clifford
Journal:  AIDS       Date:  2011-04-24       Impact factor: 4.177

6.  Markers of immune activation and viral load in HIV-associated sensory neuropathy.

Authors:  G Schifitto; M P McDermott; J C McArthur; K Marder; N Sacktor; D R McClernon; K Conant; B Cohen; L G Epstein; K Kieburtz
Journal:  Neurology       Date:  2005-03-08       Impact factor: 9.910

Review 7.  Neurological complications of HIV infection.

Authors:  Justin C McArthur; Bruce J Brew; Avi Nath
Journal:  Lancet Neurol       Date:  2005-09       Impact factor: 44.182

8.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

9.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

10.  Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex.

Authors:  D R Cornblath; J C McArthur
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

View more
  8 in total

1.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

2.  Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen.

Authors:  Anthony J Lee; Ronald J Bosch; Scott R Evans; Kunling Wu; Taylor Harrison; Philip Grant; David B Clifford
Journal:  J Neurovirol       Date:  2015-02-13       Impact factor: 2.643

3.  Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.

Authors:  Huichao Chen; David B Clifford; Lijuan Deng; Kunling Wu; Anthony J Lee; Ronald J Bosch; Sharon A Riddler; Ronald J Ellis; Scott R Evans
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

Review 4.  Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus.

Authors:  Colleen Hadigan; Sarah Kattakuzhy
Journal:  Endocrinol Metab Clin North Am       Date:  2014-09       Impact factor: 4.741

5.  Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy.

Authors:  Cecilia M Shikuma; Kara Bennett; Jintanat Ananworanich; Mariana Gerschenson; Nipat Teeratakulpisarn; Tanate Jadwattanakul; Victor DeGruttola; Justin C McArthur; Gigi Ebenezer; Nitiya Chomchey; Pairoa Praihirunkit; Piranun Hongchookiat; Pornpen Mathajittiphun; Beau Nakamoto; Peter Hauer; Praphan Phanuphak; Nittaya Phanuphak
Journal:  J Neurovirol       Date:  2015-05-22       Impact factor: 2.643

Review 6.  Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.

Authors:  Ana B Sanchez; Marcus Kaul
Journal:  Brain Sci       Date:  2017-02-23

7.  Epidemiology and factors associated with peripheral neuropathy among HIV infected patients in Gondar, Ethiopia: A cross-sectional study.

Authors:  Kedir Sany Adem; Balamurugan Janakiraman; Berihu Fisseha Gebremeskel; Mulugeta Bayisa Chala; Asmare Yitayeh Gelaw; Kassahun Alemu
Journal:  PLoS One       Date:  2019-01-29       Impact factor: 3.240

Review 8.  Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.

Authors:  Nina Y Yuan; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-06       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.